Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sofosbuvir · Sovaldi, GS-7977

Small molecule · Inhibitor of HCV NS5B polymerase · developed by Gilead Sciences

Approved FDA, Dec 2013

What is Sofosbuvir?

Sofosbuvir is a nucleotide prodrug that is converted intracellularly to its active triphosphate form, which inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase and thereby blocks viral replication. It is used in combination antiviral regimens for chronic hepatitis C virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Sovaldi, GS-7977, PSI-7977
Drug type
Small molecule
Targets
HCV NS5B polymerase
Mechanism
Inhibitor of HCV NS5B polymerase
Pathways
HCV RNA replication
Therapy area
Infectious disease
Developer
Gilead Sciences Inc
FDA status
Approved as Sovaldi (December 6, 2013), NDA204671 · FDA label
UNII
WJ6CA3ZU8B

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 26, 2024). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Hepatitis B Virus (HBV)HEPATITIS C (HCV)HIV - Human Immunodeficiency Virus

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.